T W Jones1, D Houghton2, S Cassidy2, G A MacGowan3, M I Trenell4, D G Jakovljevic5. 1. Institute of Neurosciences and Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. 2. Institute of Cellular Medicine, MoveLab, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. 3. Department of Cardiology, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK. 4. Institute of Cellular Medicine, MoveLab, Newcastle University, Newcastle upon Tyne NE2 4HH, UK RCUK Centre for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. 5. Institute of Cellular Medicine, MoveLab, Newcastle University, Newcastle upon Tyne NE2 4HH, UK RCUK Centre for Ageing and Vitality, Newcastle University, Newcastle upon Tyne NE2 4HH, UK djordje.jakovljevic@newcastle.ac.uk.
Abstract
BACKGROUND: Bioreactance is a novel noninvasive method for cardiac output measurement that involves analysis of blood flow-dependent changes in phase shifts of electrical currents applied across the thorax. The present study evaluated the test-retest reliability of bioreactance for assessing haemodynamic variables at rest and during exercise. METHODS: 22 healthy subjects (26 (4) yrs) performed an incremental cycle ergometer exercise protocol relative to their individual power output at maximal O2 consumption (Wmax) on two separate occasions (trials 1 and 2). Participants cycled for five 3 min stages at 20, 40, 60, 80 and 90% Wmax. Haemodynamic and cardiorespiratory variables were assessed at rest and continuously during the exercise protocol. RESULTS: Cardiac output was not significantly different between trials at rest (P=0.948), or between trials at any stage of the exercise protocol (all P>0.30). There was a strong relationship between cardiac output estimates between the trials (ICC=0.95, P<0.001) and oxygen consumption (ICC=0.99, P<0.001). Stroke volume was also not significantly different between trials at rest (P=0.989) or during exercise (all P>0.15), and strong relationships between trials were found (ICC=0.83, P<0.001). CONCLUSIONS: The bioreactance method demonstrates good test-retest reliability for estimating cardiac output at rest and during different stages of graded exercise testing including maximal exertion.
BACKGROUND: Bioreactance is a novel noninvasive method for cardiac output measurement that involves analysis of blood flow-dependent changes in phase shifts of electrical currents applied across the thorax. The present study evaluated the test-retest reliability of bioreactance for assessing haemodynamic variables at rest and during exercise. METHODS: 22 healthy subjects (26 (4) yrs) performed an incremental cycle ergometer exercise protocol relative to their individual power output at maximal O2 consumption (Wmax) on two separate occasions (trials 1 and 2). Participants cycled for five 3 min stages at 20, 40, 60, 80 and 90% Wmax. Haemodynamic and cardiorespiratory variables were assessed at rest and continuously during the exercise protocol. RESULTS: Cardiac output was not significantly different between trials at rest (P=0.948), or between trials at any stage of the exercise protocol (all P>0.30). There was a strong relationship between cardiac output estimates between the trials (ICC=0.95, P<0.001) and oxygen consumption (ICC=0.99, P<0.001). Stroke volume was also not significantly different between trials at rest (P=0.989) or during exercise (all P>0.15), and strong relationships between trials were found (ICC=0.83, P<0.001). CONCLUSIONS: The bioreactance method demonstrates good test-retest reliability for estimating cardiac output at rest and during different stages of graded exercise testing including maximal exertion.
Authors: R E Perkins; K G Hollingsworth; C Eggett; G A MacGowan; M G D Bates; M I Trenell; D G Jakovljevic Journal: Br J Anaesth Date: 2016-07 Impact factor: 9.166
Authors: Jodi McCoy; Matthew Bates; Christopher Eggett; Mario Siervo; Sophie Cassidy; Jane Newman; Sarah A Moore; Grainne Gorman; Michael I Trenell; Lazar Velicki; Petar M Seferovic; John G F Cleland; Guy A MacGowan; Doug M Turnbull; Djordje G Jakovljevic Journal: Open Heart Date: 2017-07-28
Authors: Maria Nathania; Kieren G Hollingsworth; Matthew Bates; Christopher Eggett; Michael I Trenell; Lazar Velicki; Petar M Seferovic; Guy A MacGowan; Doug M Turnbull; Djordje G Jakovljevic Journal: Heart Date: 2017-06-12 Impact factor: 5.994
Authors: Hugo Njemanze; Charlotte Warren; Christopher Eggett; Guy A MacGowan; Matthew G D Bates; Mario Siervo; Srdjan Ivkovic; Michael I Trenell; Djordje G Jakovljevic Journal: Oncotarget Date: 2016-11-22
Authors: Sarah J Charman; Nduka C Okwose; Renae J Stefanetti; Kristian Bailey; Jane Skinner; Arsen Ristic; Petar M Seferovic; Mike Scott; Stephen Turley; Ahmet Fuat; Jonathan Mant; Richard F D Hobbs; Guy A MacGowan; Djordje G Jakovljevic Journal: ESC Heart Fail Date: 2018-06-26
Authors: Milos Parovic; Nduka C Okwose; Kristian Bailey; Lazar Velicki; Zlatko Fras; Petar M Seferovic; Guy A MacGowan; Djordje G Jakovljevic Journal: ESC Heart Fail Date: 2019-02-20
Authors: David Houghton; Thomas W Jones; Sophie Cassidy; Mario Siervo; Guy A MacGowan; Michael I Trenell; Djordje G Jakovljevic Journal: Mech Ageing Dev Date: 2015-11-15 Impact factor: 5.432
Authors: Sarah A Moore; Djordje G Jakovljevic; Gary A Ford; Lynn Rochester; Michael I Trenell Journal: Arch Phys Med Rehabil Date: 2016-01-04 Impact factor: 3.966
Authors: Jose Suryanegara; Sophie Cassidy; Vladan Ninkovic; Dejana Popovic; Miljan Grbovic; Nduka Okwose; Michael I Trenell; Guy G MacGowan; Djordje G Jakovljevic Journal: Acta Diabetol Date: 2018-11-01 Impact factor: 4.280